Q2 2026 Alamar Biosciences Inc Earnings Call Transcript

Aug 10, 2026 / 08:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Total revenue grew 82% year-over-year to $29.4 million, driven by exceptional consumable performance which surged 147%.
Achieved a record 60% gross margin, up from 53% in the prior year, due to manufacturing efficiencies and a favorable product mix shift toward higher-margin consumables.
Launched the first commercial multiplex blood-based immunoassay for eMTBR tau, a key Alzheimer's biomarker, positioning the company at the forefront of neurodegenerative disease research.
Expanded strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to profile an additional 86,000 plasma samples, bringing the combined dataset to over 140,000 samples.
Ended the quarter with a strong balance sheet of $256.3 million in cash and short-term investments, providing ample capital to execute growth plans and invest in R&D and commercial expansion.
Surpassed 165 cumulative publications and preprints, with a four-fold increase in posters featuring its technology at AAIC, demonstrating growing scientific validation and adoption.
Launched the NuLISA-Seq Immune 340 panel, the broadest multiplex immune profiling panel, opening a large and under-penetrated market opportunity in immunology.
Maintained industry-leading instrument pull-through above $400,000, with a theoretical ceiling of $5-6 million per instrument, indicating strong customer engagement and platform utilization.
Refinanced existing debt into a more flexible $100 million revolving credit facility with improved terms, enhancing financial flexibility.
Provided full-year 2026 revenue guidance of $116 million to $120 million, reflecting expected annual growth of 59% at the midpoint.

Negative

Net loss widened to $13.2 million in Q2 2026, up from $7 million in Q2 2025, reflecting increased operating expenses.
SG&A expenses surged 129% year-over-year to $17.4 million, driven by higher personnel costs and professional services fees associated with operating as a public company.
R&D expenses increased 55% to $13.8 million, reflecting higher lab supply costs and personnel expenses to support expanding panel menu and product development.
The company expects gross margin to fluctuate in the mid-to-high 50s in the near term, indicating that the record 60% margin may not be sustained immediately.
Q3 2026 revenue is expected to show only a modest sequential increase (low single-digit growth), suggesting a potential slowdown in momentum after a strong Q2.
The Technology Access Program (TAP) revenue, which drove significant upside in Q2, is expected to grow at a slower rate going forward as the company focuses on converting customers to instrument purchases.
Instrument revenue growth of 35% lagged overall revenue growth, indicating a potential shift in revenue mix that could pressure near-term margins.
The company faces execution risks in its ambitious 2027 goals, including FDA marketing authorization for ArgoHTDx and establishing clinical diagnostic partnerships, which are subject to regulatory and market uncertainties.
Large cohort study revenues are subject to long lead times and logistical complexities, which could cause revenue recognition to be lumpy and unpredictable across quarters.
The passing of Board member Ian Radcliffe represents a loss of experienced leadership and guidance for the company.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALMR.OQ - Alamar Biosciences Inc
Q2 2026 Alamar Biosciences Inc Earnings Call
Aug 10, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, and thank you for standing by. Welcome to the Alamar Biosciences Second Quarter 2026 Financial Results Webcast Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Carrie Mandeville, Vice President of Investor Relations and Corporate Communications. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, everyone,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.